leadf
logo-loader
viewJohnson & Johnson

J&J, world's largest healthcare firm, agrees US$30bn deal to buy Actelion, Europe’s biggest biotech group

J&J is paying $280 a share in cash for Actelion, retaining the Swiss firm's commercially available treatments for rare diseases such as pulmonary arterial hypertension.

J&J baby oil bottle
Actelion will spin off its drug-discovery operations into a separate company called R&D NewCo, in which J&J will initially hold a 16% stake

The world’s largest healthcare firm Johnson & Johnson (NYSE:JNJ) has agreed a US$30bn deal to buy Europe’s biggest biotech firm, Actelion Pharmaceuticals Ltd.

J&J is paying $280 a share in cash for Actelion, retaining the Swiss company's commercially available treatments for rare diseases such as an artery disorder known as pulmonary arterial hypertension.

However, Actelion will spin off its drug-discovery operations into a separate company called R&D NewCo, in which J&J will initially hold a 16% stake, with an option to acquire another 16%.

READ: J&J’s change of heart …

The takeover deal comes after J&J had a surprising a change of heart just before Christmas and re-entered acquisition talks with Actelion.

J&J had abruptly bowed out of the bidding process for Actelion earlier in the month after the Swiss firm said that it was “engaged in discussions with another party”.

Actelion had given no details about who the third party was, but press reports at the time suggested it was French firm Sanofi SA.

However, J&J said it had entered into “exclusive negotiations” to acquire the Swiss firm, indicating that other potential suitors had left the process.

Quick facts: Johnson & Johnson

Price: 144.24 USD

NYSE:JNJ
Market: NYSE
Market Cap: $379.92 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Chesapeake Financial Shares boosts 3Q earnings from year ago quarter

Chesapeake Financial Shares Inc (OTCQX:CPKF) CEO Jeffrey Szyperski tells Proactive the group reported third-quarter earnings of $3.38 million, a 4.8% year-over-year increase. Szyperski says the bank ' has had a good 2020 thus far' adding that coming off of a record year in 2019, the group is...

19 minutes ago

2 min read